Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 563


Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.

Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR.

Biol Blood Marrow Transplant. 2006 Nov;12(11):1150-60.


Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.

MacDonald KP, Rowe V, Filippich C, Thomas R, Clouston AD, Welply JK, Hart DN, Ferrara JL, Hill GR.

Blood. 2003 Mar 1;101(5):2033-42. Epub 2002 Oct 17.


Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease.

Fowler DH, Foley J, Whit-Shan Hou J, Odom J, Castro K, Steinberg SM, Gea-Banacloche J, Kasten-Sportes C, Gress RE, Bishop MR.

Clin Gastroenterol Hepatol. 2004 Mar;2(3):237-45.


Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants.

Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S, Aversa F, Tabilio A, Romani L, Martelli MF, Velardi A.

Blood. 2001 Apr 15;97(8):2514-21.


Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.

Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR.

Blood. 2013 Apr 11;121(15):2864-74. doi: 10.1182/blood-2012-08-446872. Epub 2013 Feb 20.


Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells.

Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C.

Blood. 2000 Apr 15;95(8):2484-90.


Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.

Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL.

J Immunol. 1995 Jul 15;155(2):585-93.


Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells.

Fowler DH, Bishop MR, Gress RE.

Semin Oncol. 2004 Feb;31(1):56-67. Review.


Expansion of CD4+CD7- T cells, a memory subset with preferential interleukin-4 production, after bone marrow transplantation.

Leblond V, Othman TB, Blanc C, Theodorou I, Choquet S, Sutton L, Debré P, Autran B.

Transplantation. 1997 Nov 27;64(10):1453-9.


[Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].

Huang HQ, Cai QC, Shi YX, Lin XB, Wei J, Guo Y, Pan ZH.

Ai Zheng. 2006 Aug;25(8):1023-8. Chinese.


Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.

Jung U, Foley JE, Erdmann AA, Toda Y, Borenstein T, Mariotti J, Fowler DH.

Biol Blood Marrow Transplant. 2006 Sep;12(9):905-18.


Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients.

Shindo T, Ishikawa T, Fukunaga A, Hori T, Uchiyama T.

Biol Blood Marrow Transplant. 2008 Mar;14(3):268-81. doi: 10.1016/j.bbmt.2007.12.004.


Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.

Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.

Transplantation. 2009 Dec 15;88(11):1312-8. doi: 10.1097/TP.0b013e3181bbf382.


Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.

Min CK, Maeda Y, Lowler K, Liu C, Clouthier S, Lofthus D, Weisiger E, Ferrara JL, Reddy P.

Blood. 2004 Nov 15;104(10):3393-9. Epub 2004 Jul 27.


Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.

Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J.

Biol Blood Marrow Transplant. 2002;8(11):625-32.


Supplemental Content

Support Center